Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Biomarker Type

  2.3.2 Market Size by Diagnostic Technique

  2.3.3 Market Size by Application

  2.3.4 Market Size by End-User

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

     3.4 Industry Supply Chain Analysis

3.4.1 Reagent, Assay Kit & Biomarker Technology Suppliers

3.4.2 Biomarker Developers & Diagnostic Solution Providers

3.4.3 CROs, Laboratory Service Providers & Distribution Partners

3.4.4 Pharmaceutical Companies, Research Institutes, Hospitals & Diagnostic Centers

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 NASH Disease Burden & Patient Population Trends (2025)

4.1.1 Global Prevalence of NASH and NAFLD Patients

4.1.2 Incidence of Advanced Fibrosis and Cirrhosis Associated with NASH

4.1.3 Obesity, Diabetes, and Metabolic Syndrome Correlation Trends

4.1.4 Regional Disease Burden Analysis

4.2 NASH Diagnostic & Biomarker Adoption Trends (2025)

4.2.1 Non-Invasive Diagnostic Test Utilization Trends

4.2.2 Biomarker Adoption in Clinical Practice

4.2.3 Blood-Based vs. Imaging-Based Diagnostic Preferences

4.2.4 Early Detection and Risk Stratification Trends

4.3 Clinical Trials & Drug Development Trends (2025)

4.3.1 Biomarker Utilization in NASH Clinical Trials

4.3.2 Patient Enrollment Trends in NASH Studies

4.3.3 Companion Diagnostic Development Trends

4.3.4 Regulatory Support for Biomarker-Based Endpoints

4.4 Healthcare Spending & Screening Trends (2025)

4.4.1 Spending on Liver Disease Diagnostics

4.4.2 Screening Rates Among High-Risk Populations

4.4.3 Hospital and Diagnostic Laboratory Testing Trends

4.4.4 Reimbursement Trends for NASH Biomarker Testing

4.5 Precision Medicine & Innovation Trends (2025)

4.5.1 Multi-Biomarker Panel Development Trends

4.5.2 Genomic, Proteomic & Metabolomic Biomarker Research

4.5.3 AI-Driven NASH Risk Prediction and Diagnostic Models

4.5.4 Patent Filings and Research Collaborations in NASH Biomarkers

5. Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmental Analysis & Forecast, By Biomarker Type, 2022 – 2035, Value (USD Billion)

     5.1 Introduction

   5.2 Serum Biomarkers

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022 – 2035

5.3 Hepatic Fibrosis Biomarkers

5.4 Oxidative Stress Biomarkers

5.5 Apoptosis Biomarkers

5.6 Genomic/Proteomic Biomarkers

5.7 Others

6. Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmental Analysis & Forecast, By Diagnostic Technique, 2022 – 2035, Value (USD Billion)

    6.1 Introduction

    6.2 Imaging Biomarkers

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022 – 2035

6.3 Serum-Based Testing

6.4 Histological Biomarkers

7. Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmental Analysis & Forecast, by Application, 2022 – 2035, Value (USD Billion)

    7.1 Introduction

    7.2 Drug Development

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022 – 2035

7.3 Clinical Diagnosis

7.4 Research Applications

8. Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmental Analysis & Forecast, By End-User, 2022 – 2035, Value (USD Billion)

    8.1 Introduction 

  8.2 Pharmaceutical Companies & CROs

   8.2.1 Key Trends 

   8.2.2 Market Size & Forecast, 2022 – 2035 

8.3 Research Institutes & Academics

8.4 Hospitals & Diagnostic Centres

9. Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Segmental Analysis & Forecast by Region, 2022 – 2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Biomarker Type, 2022 – 2035

 9.2.3 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Diagnostic Technique, 2022 – 2035

 9.2.4 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, by Application, 2022 – 2035

 9.2.5 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By End-User, 2022 – 2035

 9.2.6 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Country, 2022 – 2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Biomarker Type, 2022 – 2035

 9.3.3 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Diagnostic Technique, 2022 – 2035

 9.3.4 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, by Application, 2022 – 2035

 9.3.5 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By End-User, 2022 – 2035

 9.3.6 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Country, 2022 – 2035

  9.3.6.1 Germany

  9.3.6.2 United Kingdom

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Biomarker Type, 2022 – 2035

 9.4.3 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Diagnostic Technique, 2022 – 2035

 9.4.4 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, by Application, 2022 – 2035

 9.4.5 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By End-User, 2022 – 2035

 9.4.6 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Country, 2022 – 2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Biomarker Type, 2022 – 2035

 9.5.3 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Diagnostic Technique, 2022 – 2035

 9.5.4 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, by Application, 2022 – 2035

 9.5.5 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By End-User, 2022 – 2035

 9.5.6 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Country, 2022 – 2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Biomarker Type, 2022 – 2035

 9.6.3 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Diagnostic Technique, 2022 – 2035

 9.6.4 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, by Application, 2022 – 2035

 9.6.5 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By End-User, 2022 – 2035

 9.6.6 Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Forecast, By Country, 2022 – 2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 Egypt

  9.6.6.5 South Africa

  9.6.6.6 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022 – 2025

  10.2.3 Number of Strategies Adopted by Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Network Type Benchmarking

  10.4.1 Product/Service Specifications & Features by Key Players

  10.4.2 Product/Service Heatmap by Key Players

  10.4.3 Network Type Heatmap by Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 GENFIT S.A.

  10.6.1.1 Company Overview & Snapshot

  10.6.1.2 Product/Service Portfolio

  10.6.1.3 Key Company Financials

  10.6.1.4 SWOT Analysis

10.6.2 Prometheus Laboratories Inc.

10.6.3 Quest Diagnostics

10.6.4 Labcorp Holdings

10.6.5 Siemens Healthineers

10.6.6 BioPredictive S.A.S.

10.6.7 Madrigal Pharmaceuticals

10.6.8 Gilead Sciences

10.6.9 Novo Nordisk

10.6.10 AstraZeneca

10.6.11 Pfizer Inc.

10.6.12 Bristol-Myers Squibb

10.6.13 Abbott Laboratories

10.6.14 Roche Diagnostics

10.6.15 Hologic Inc.

10.6.16 Exalenz Bioscience Ltd.

10.6.17 Norgine B.V.

10.6.18 Novartis AG

10.6.19 Allergan (AbbVie)

10.6.20 Intercept Pharmaceuticals

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List of Tables

 14.2 List of Figures